JBCHEPHARM
JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) Stock Analysis
JB Chemicals & Pharmaceuticals Limited makes branded generics and APIs in cardiovascular, gastro, and CNS therapies. It has Indian and Russian operations with growing consumer health brands. The company is owned by Torrent Pharma but remains separately listed in India.
₹2,416.10
+0.00% 1W | +39.60% 52W
Market Cap
38.8k CR
P/E Ratio
54.2
52W High
₹2525.5
52W Low
₹1638.5
Div. Yield
0%
Beta
0
50 DMA
₹2271.1
200 DMA
₹2003.1
Profit Margin
17.1%
Inst. Own.
30.8%
🚀 BREAKOUT
🚀 BREAKOUT
Fundamentals
Profit & Loss
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 762 | 896 | 882 | 845 | 862 | 1,004 | 1,001 | 963 | 949 | 1,094 | 1,085 | 1,065 | 904 |
| Expenses | 599 | 664 | 638 | 621 | 664 | 724 | 730 | 709 | 723 | 793 | 775 | 769 | 703 |
| Operating Profit | 164 | 232 | 244 | 223 | 198 | 280 | 271 | 255 | 226 | 301 | 310 | 296 | 201 |
| OPM % | 21% | 26% | 28% | 26% | 23% | 28% | 27% | 26% | 24% | 28% | 29% | 28% | 22% |
| Other Income | 5 | 6 | 8 | 7 | 17 | 6 | 10 | 8 | 14 | 15 | 15 | 18 | -15 |
| Interest | 14 | 12 | 10 | 12 | 9 | 6 | 2 | 3 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 32 | 31 | 32 | 34 | 41 | 41 | 42 | 42 | 46 | 43 | 44 | 45 | 50 |
| Profit before tax | 122 | 194 | 209 | 184 | 165 | 240 | 237 | 218 | 193 | 272 | 279 | 267 | 135 |
| Tax % | 28% | 27% | 28% | 27% | 23% | 26% | 26% | 25% | 25% | 25% | 26% | 26% | 25% |
| Net Profit | 88 | 142 | 151 | 134 | 126 | 177 | 175 | 162 | 146 | 202 | 208 | 198 | 101 |
| EPS in Rs | 5.66 | 9.19 | 9.72 | 8.62 | 8.13 | 11.39 | 11.24 | 10.45 | 9.36 | 12.96 | 13.27 | 12.63 | 6.31 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,144 | 1,210 | 1,344 | 1,408 | 1,643 | 1,775 | 2,043 | 2,424 | 3,149 | 3,484 | 3,918 | 4,148 |
| Expenses | 964 | 1,004 | 1,112 | 1,191 | 1,337 | 1,397 | 1,482 | 1,881 | 2,454 | 2,587 | 2,886 | 3,040 |
| Operating Profit | 180 | 206 | 232 | 218 | 306 | 378 | 560 | 543 | 696 | 897 | 1,032 | 1,107 |
| OPM % | 16% | 17% | 17% | 15% | 19% | 21% | 27% | 22% | 22% | 26% | 26% | 27% |
| Other Income | 11 | 58 | 50 | 37 | 41 | 41 | 112 | 39 | 10 | 37 | 38 | 33 |
| Interest | 7 | 11 | 5 | 3 | 5 | 3 | 7 | 5 | 36 | 44 | 12 | 6 |
| Depreciation | 39 | 41 | 47 | 57 | 56 | 66 | 69 | 73 | 114 | 138 | 171 | 182 |
| Profit before tax | 146 | 212 | 230 | 194 | 287 | 349 | 597 | 505 | 555 | 752 | 887 | 952 |
| Tax % | 31% | 23% | 20% | 28% | 32% | 22% | 25% | 24% | 26% | 26% | 26% | 26% |
| Net Profit | 100 | 163 | 184 | 139 | 194 | 272 | 449 | 386 | 410 | 553 | 660 | 709 |
| EPS in Rs | 5.92 | 9.58 | 10.85 | 8.27 | 12.06 | 17.60 | 28.98 | 24.93 | 26.48 | 35.61 | 42.36 | 44.18 |
| Dividend Payout % | 118% | 26% | 5% | 12% | 21% | 31% | 28% | 33% | 34% | 34% | 37% | 50% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 10.0% | 15.0% | 13.0% |
| Profit CAGR | 21.0% | 12.0% | 18.0% |
Shareholding Pattern
Promoters47.84%
FIIs18.30%
DIIs18.71%
Public15.13%
Promoters47.73%
FIIs17.77%
DIIs19.62%
Public14.87%
Promoters47.56%
FIIs15.31%
DIIs22.83%
Public14.31%
Promoters47.55%
FIIs14.88%
DIIs23.35%
Public14.21%
Promoters48.80%
FIIs16.33%
DIIs21.38%
Public13.48%
Promoters54.00%
FIIs9.22%
DIIs16.89%
Public19.89%
Promoters53.93%
FIIs8.62%
DIIs19.08%
Public18.35%
Promoters53.78%
FIIs11.06%
DIIs18.38%
Public16.78%
Promoters47.84%
FIIs18.30%
DIIs18.71%
Public15.13%
Promoters48.80%
FIIs16.33%
DIIs21.38%
Public13.48%
JBCHEPHARM
Holdings Analysis
Key strengths & risk signals
71
Overall
73
Fundamental
69
Technical
Risks (2)
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
BEARISH SENTIMENT! In last 30 days: 18 up days, 7 down days. Avg volume on up days: 409,655 vs down days: 935,268. Ratio: 0.44x
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (2271.1) is above 200-day average (2003.1) - positive signal.
BREAKOUT! Stock has broken above resistance levels with momentum.
GOOD YEAR! Stock gained 39.6% in the last year.
Fundamental & Technical Analysis
71Overall
73Fundamental
69Technical
Fundamental Breakdown
Growth Quality
23/30
Revenue CAGR: 9.4% (MODERATE, 8/15). Profit CAGR: 20.1% (EXCELLENT, 15/15).
Profit Margin
6/10
GOOD EFFICIENCY! 17.1% profit margin - above average profitability.
PEG Valuation
5/10
OVERVALUED! PEG of 2.70 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.01 - excellent financial health.
Public Holding
16/20
LESS PUBLIC HOLDING! 17.9% public ownership - good institutional/promoter control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (2271.1) is above 200-day average (2003.1) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (2416.1) is above both moving averages.
Trend Pattern
20/20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance
10/10
GOOD YEAR! Stock gained 39.6% in the last year.
Volume Sentiment
5/30
BEARISH SENTIMENT! In last 30 days: 18 up days, 7 down days. Avg volume on up days: 409,655 vs down days: 935,268. Ratio: 0.44x
RSI
3/5
BULLISH! RSI at 61.0 - positive momentum.
52W Range
5/5
STRONG! Trading at 87.7% of 52W range - near yearly highs.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - 0.0% (1 week), 7.7% (1 month), 20.1% (3 months).
Beta
3/5
MARKET ALIGNED! Beta of 1.00 - moves with the market.
JBCHEPHARM
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-05-13 | Concall PDF | |
| Q2FY262026-01-21 | Concall PDF |
Peer Comparison
· · 1 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JBCHEPHARM | ₹2,416.10 | 54.2 | 17.1% | 9.4% | 20.1% | +39.6% | 71 | BREAKOUT | -30.4% | -48.8% | -4.8% | -15.1% |
Data from TradeAlone · Updated daily
No news tagged for JBCHEPHARM yet.
